Peyronie's disease response to intralesional collagenase clostridium histolyticum therapy is independent of baseline testosterone.
Peyronie's disease
hypogonadism
intralesional collagenase clostridium histolyticum
testosterone
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
27 Sep 2023
27 Sep 2023
Historique:
revised:
05
08
2023
received:
21
01
2023
accepted:
06
09
2023
pubmed:
27
9
2023
medline:
27
9
2023
entrez:
27
9
2023
Statut:
aheadofprint
Résumé
Testosterone plays an important role in collagen metabolism, transforming growth factor-β1 expression, and wound healing, which are all critical factors in pathogenesis of Peyronie's disease. Some clinical studies have suggested an association between Peyronie's disease and hypogonadism. We sought to investigate whether baseline total testosterone levels influence response to intralesional collagenase clostridium histolyticum in Peyronie's disease. A retrospective review of patients receiving collagenase clostridium histolyticum injections with available total testosterone levels within 1 year of initial injection was conducted at a single institution. Baseline demographics, hypogonadal status, total testosterone, number of collagenase clostridium histolyticum cycles, and pre- and post-treatment degrees of curvature were collected. Hypogonadism was defined as total testosterone <300 ng/dL. Thirty-six men were included with mean age of 58.2 years (SD 10.4) and mean body mass index 26.8 (SD 3.2). The mean total testosterone was 459.2 ng/dL (SD 144.0), and four (11.1%) were hypogonadal. Mean pre-treatment curvature was 47.6°, and mean post-treatment curvature was 27.8°, with mean improvement of 19.9° (40.1%). Hypogonadal status was not significantly associated with more severe curvature, 46.4° among hypogonadal men as to 57.5° among eugonadal men (p = 0.32). On linear regression analysis, total testosterone did not significantly predict improvement in degrees (β = -0.02; R Neither total testosterone nor hypogonadism is associated with a degree of improvement after collagenase clostridium histolyticum treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Testosterone plays an important role in collagen metabolism, transforming growth factor-β1 expression, and wound healing, which are all critical factors in pathogenesis of Peyronie's disease. Some clinical studies have suggested an association between Peyronie's disease and hypogonadism.
OBJECTIVE
OBJECTIVE
We sought to investigate whether baseline total testosterone levels influence response to intralesional collagenase clostridium histolyticum in Peyronie's disease.
METHODS
METHODS
A retrospective review of patients receiving collagenase clostridium histolyticum injections with available total testosterone levels within 1 year of initial injection was conducted at a single institution. Baseline demographics, hypogonadal status, total testosterone, number of collagenase clostridium histolyticum cycles, and pre- and post-treatment degrees of curvature were collected. Hypogonadism was defined as total testosterone <300 ng/dL.
RESULTS AND DISCUSSION
CONCLUSIONS
Thirty-six men were included with mean age of 58.2 years (SD 10.4) and mean body mass index 26.8 (SD 3.2). The mean total testosterone was 459.2 ng/dL (SD 144.0), and four (11.1%) were hypogonadal. Mean pre-treatment curvature was 47.6°, and mean post-treatment curvature was 27.8°, with mean improvement of 19.9° (40.1%). Hypogonadal status was not significantly associated with more severe curvature, 46.4° among hypogonadal men as to 57.5° among eugonadal men (p = 0.32). On linear regression analysis, total testosterone did not significantly predict improvement in degrees (β = -0.02; R
CONCLUSION
CONCLUSIONS
Neither total testosterone nor hypogonadism is associated with a degree of improvement after collagenase clostridium histolyticum treatment.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 American Society of Andrology and European Academy of Andrology.
Références
Peak TC, Mitchell GC, Yafi FA, et al. Role of collagenase clostridium histolyticum in Peyronie's disease. Biol Targets Ther. 2015;9:107-116.
Tsambarlis P, Levine LA. Nonsurgical management of Peyronie's disease. Nat Rev Urol. 2019;16:172-186.
Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie's disease: AUA guideline. J Urol. 2015;194:745-753.
Cwikla DJ, Yafi FA. Intralesional collagenase Clostridium histolyticum in the management of Peyronie's disease: current best practice. Ther Adv Urol. 2018;10:139-153.
Shlykova N, Morgentaler A. Augmenting intralesional collagenase treatment with testosterone therapy provides greater self-assessed improvement in penile curvature due to Peyronie's disease. Androg Clin Res Ther. 2020;1:70-75.
Aditya I, Grober ED, Krakowsky Y. Peyronie's disease and testosterone deficiency: is there a link? World J Urol. 2019;37:1035-1041.
Krakhotkin DV, Chernylovskyi VA, Mottrie A, et al. New insights into the pathogenesis of Peyronie's disease: a narrative review. Chronic Dis Transl Med. 2020;6:165-181.
Traish AM. Androgens play a pivotal role in maintaining penile tissue architecture and erection: a review. J Androl. 2009;30:363-369.
Armagan A, Hatsushi K, Toselli P. The effects of testosterone deficiency on the structural integrity of the penile dorsal nerve in the rat. Int J Impot Res. 2008;20:73-78.
Gelbard M, Goldstein I, Hellstrom WJG, et al. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199-207.
Traish A, Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med. 2005;2:759-770.
Montorsi F, Briganti A, Salonia A, et al. The ageing male and erectile dysfunction: the ageing male and erectile dysfunction. BJU Int. 2003;92:516-520.
Iacono F, Prezioso D, Ruffo A, et al. Testosterone deficiency causes penile fibrosis and organic erectile dysfunction in aging men. Evaluating association among age, TDS and ED. BMC Surg. 2012;12:S24.
Candela L, Boeri L, Capogrosso P, et al. Serum testosterone levels are not associated with the severity of penile curvature in men with Peyronie's disease-findings from a cross-sectional study. Int J Impot Res. 2020;33:832-838.
Mitsui Y, Yamabe F, Hori S, et al. Significant inverse association of testosterone level with penile deformity severity in Japanese males with Peyronie's disease. Int J Urol. 2023;30:36-42.
Mulhall JP, Matsushita K, Nelson CJ. Testosterone levels are not associated with magnitude of deformity in men with Peyronie's disease. J Sex Med. 2019;16:1283-1289.
Anaissie J, Yafi FA, DeLay KJ, et al. Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie's disease. Urology. 2017;100:125-130.
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423-432.